Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: Updated survival results and subgroup analyses from the BEACON study

by on 1 de març de 2021 with No hi ha comentaris
  • Tabernero, J., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., . . . Kopetz, S. (2021). Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: Updated survival results and subgroup analyses from the BEACON study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 39(4), 273-284. https://doi.org/10.1200/JCO.20.02088

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *